Entera Bio Ltd - חוב לטווח קצר של החברה ENTX

The resilience of Entera Bio Ltd. (ENTX) is driven by colossal demand from pharma giants for the replacement of injections with tablets. Financial obligations with a maturity of up to one year demonstrate current liquidity, with the indicator holding around 0.00. Growth is fueled by successful tests of an oral hormone for osteoporosis and licensing. Automated biotech platforms enhance business efficiency by minimizing manual labor during drug encapsulation.

Entera Bio Ltd. focuses on developing an innovative oral protein delivery system, the monetization of which is deferred until the completion of clinical trials and the execution of B2B contracts. Monitoring the aggregate of liabilities maturing within one year via the level of short-term obligations allows for an assessment of the company's liquidity risk, determining its ability to fund R&D without emergency capital raises in the absence of current sales.